Designing Best in Class TCR Cell Therapies Against Novel Antigens

Time: 12:20 pm
day: Focus Day


• Identifying the nuances of neoantigen TCR-based therapies to allow acceleration to the clinic
• Importance of diversity for identifying first in class targets and best in class T cell receptors while minimizing off-target toxicity.
• Characterizing T cell receptors with the ideal binding profile.
• Utilization of a mass spectrometry independent yeast display platform that leverages in silico based prediction models to de-risk T
cell receptor cell therapies.